Category Archives: Stem Cell Medicine

Election 2020: Prop. 14 and stem cell research funding – KCBX

In November, California voters will be deciding on a dozen statewide ballot measures. One is about funding stem cell research through bonds, Proposition 14.

Just one day before his high school graduation, Cal Poly football recruit Jake Javier dove into a friends swimming pool and hit his head on the bottom, leaving him paralyzed from the chest down.

The next thing I knew I was being told Im a quadriplegic,” Javier said. “I broke my neck at the C6 level.

Javiers plans to play football in collegenow gone. He was told he was never going to walk again.

I really didnt have time to panic, or feel sorry for myself,” Javier said. “Immediately it was survival mode for the next couple weeks, I was on a ventilator [and] couldnt breathe, and then from there it was starting my rehab.

Less than a week post-injury, he got a call from a Stanford doctor who said the teen would make a great candidate for a stem cell trial they were conducting.

They were very clear about the possible outcomes of it,” Javier said. “They were like yeah it could potentially help you we dont know how much, it could potentially negatively affect you and hurt your function.'”

Javier decided even if it wouldnt help him, the research could help others, so he became a part of the trial. Doctors injected stem cells in him in a one-time surgery, then monitored and tested Javier’s progress for months. He says he had a positive outcome.

I regained more strength in my arms than what was expected, I have a little bit of finger movement that isnt a whole lot, but it’s functional,” Javier said. “Honestly Im really glad I went through with it because I have no idea where Id be without it.

This election, California voters will decide whether to pay for more stem cell research like this via Proposition 14. It continues programs approved by voters in 2004.

A UC San Diego professor of cellular and molecular medicine, Lawrence Goldstein, says it will fund research and therapy for Alzheimers, Parkinsons, cancer, and other brain and central nervous system diseases and conditions.

It would authorize five and a half billion dollars,” Goldstein said. “In what are called general obligation funds that would then be used to fund stem cell research in medicine.

Opponents argue with California facing a huge budget deficit due to the pandemic, Prop. 14 would take billions away from more pressing needs like housing and education. And that back in 2004, state voters approved funding because the federal government wasnt supporting stem cell research, but thats no longer the case.

See the original post:
Election 2020: Prop. 14 and stem cell research funding – KCBX

Hair Regeneration Therapy Company Stemson Therapeutics Raises $7.5 Million – Pulse 2.0

Stemson Therapeutics announced that it has raised a $7.5 million seed round of funding led by Allergan Aesthetics (an AbbVie Company) and impact investor Fortunis Capital to advance the development of Stemsons therapeutic solution to cure hair loss. This funding round enables Stemson to advance its goal of restoring human hair growth with a novel approach using the patients own cells to generate new hair follicles.

Allergan Aesthetics is known as a world-leading medical aesthetics company. And Fortunis Capital is committed to continuing support of Stemsons regenerative cell therapy to treat hair loss through its new Impact Fund which intends to invest in companies that offer significant social or environmental benefit.

The seed funding round supports the preclinical development of Stemsons Induced Pluripotent Stem Cell (iPSC) based technology which is capable of producing the cell types required to initiate hair follicle growth. And globally, hundreds of millions of men and women suffer from various forms of hair loss and no solution today is capable of generating a new supply of follicles for patients in need.

The initial seed financing round enables Stemson to expand its management team and R&D resources while recent approval of a foundational patent provides stability surrounding the companys efforts to develop its radical solution for hair growth. The additions of Meghan Samberg, Ph.D. as Vice President of R&D and Preclinical Development and Cenk Sumen, Ph.D. as Chief Technology Officer complement the work of Stemsons cofounder and Chief Scientific Officer Dr. Alexey Terskikh and the R&D team.

Stemson received approval in the United States of its cornerstone Human Induced Pluripotent Stem Cell (iPSC) method patent licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute. And the patent covers a novel process developed by Dr. Terskikh to differentiate iPSC into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling. The patent secures foundational methods using iPSC cell therapy to grow hair.


Stemsons novel cell therapy approach to treat hair loss has game-changing potential. Their experienced management team is poised to elevate its proprietary regenerative cell therapy method as it begins the next phase of its preclinical program. Fortunis Capital is committed to supporting companies that are creating innovative solutions with worldwide social or environmental benefit, and we believe that Stemson has the team, technology and the tools in place to develop a therapy capable of solving the hair loss problem for millions of people in need.

Sir Andrew Ross, Director of Investments at Fortunis Capital

Allergan Aesthetics research and development efforts are focused on products and technologies that drive the advancement of aesthetics medicine. Hair loss is a significant unmet medical need for millions of men and women, and Stemson Therapeutics efforts to develop novel methods to regrow hair is an opportunity to make a difference in this area.

Yehia Hashad, M.D. Senior Vice President, Research and Development, Allergan Aesthetics.

Stemson has established the biological and technical building blocks which are needed to solve the problem of hair loss. A truly curative solution is now feasible, and we have built a world-class team to deliver a therapy for the millions of hair loss sufferers across the world. We are grateful for support from Allergan Aesthetics and Fortunis Capital, and we look forward to expanding our base of investors as we move toward our first human clinical trial.

Geoff Hamilton, cofounder and chief executive officer of Stemson Therapeutics

Excerpt from:
Hair Regeneration Therapy Company Stemson Therapeutics Raises $7.5 Million – Pulse 2.0

Intestinal Organoid Built That Looks and Functions Like Real Tissue – Genetic Engineering & Biotechnology News

Organoids, which originate from stem cells, are a tool with great potential for modeling tissue and disease biology. The idea is to build miniature tissues and organs that accurately resemble and behave like their real counterparts. But there have been limitations to their development. A new study has taken organoids a step further by inducing intestinal stem cells to form tube-shaped epithelia with an accessible lumen and a similar spatial arrangement of crypt- and villus-like domains to that in vivo. These mini-intestines also retain key physiological hallmarks of the intestine and have a notable capacity to regenerate.

The work is published in Nature in the paper titled, Homeostatic mini-intestines through scaffold-guided organoid morphogenesis.

Organoids could complement animal testing by providing healthy or diseased human tissues, expediting the lengthy journey from lab to clinical trial. Beyond that, organoid technology may hold promise, in the long-term, to replace damaged tissues or even organs in the future. For example, by taking stem cells from a patient and growing them into a new liver, heart, kidney, or lung.

So far, established methods of making organoids come with considerable drawbacks: stem cells develop uncontrollably into circular and closed tissues that have a short lifespan, as well as non-physiological size and shape, all of which result in overall anatomical and/or physiological inconsistency with real-life organs.

Now, scientists from the group led by Matthias Ltolf, PhD, professor at EPFLs Institute of Bioengineering, have found a way to guide stem cells to form an intestinal organoid that looks and functions just like real tissue. The method exploits the ability of stem cells to grow and organize themselves along a tube-shaped scaffold that mimics the surface of the native tissue, placed inside a microfluidic chip.

The researchers used a laser to sculpt the gut-shaped scaffold within a hydrogel, a soft mix of crosslinked proteins found in the guts extracellular matrix supporting the cells in the native tissue. Aside from being the substrate on which the stem cells could grow, the hydrogel thus also provides the form or geometry that would build the final intestinal tissue.

Once seeded in the gut-like scaffold, within hours, the stem cells spread across the scaffold, forming a continuous layer of cells with its characteristic crypt structures and villus-like domains. Then came a surprising result: the scientists found that the stem cells arranged themselves in order to form a functional tiny gut.

It looks like the geometry of the hydrogel scaffold, with its crypt-shaped cavities, directly influences the behavior of the stem cells so that they are maintained in the cavities and differentiate in the areas outside, just like in the native tissue, said Ltolf. The stem cells didnt just adapt to the shape of the scaffold, they produced all the key differentiated cell types found in the real gut, with some rare and specialized cell types normally not found in organoids.

Intestinal tissues are known for the highest cell turnover rates in the body, resulting in a massive amount of shed dead cells accumulating in the lumen of the classical organoids that grow as closed spheres and require weekly breaking down into small fragments to maintain them in culture. The introduction of a microfluidic system allowed us to efficiently perfuse these mini-guts and establish a long-lived homeostatic organoid system in which cell birth and death are balanced, said Mike Nikolaev, a graduate student and the first author of the paper.

The researchers demonstrated that these miniature intestines share many functional features with their in vivo counterparts. For example, they can regenerate after massive tissue damage and they can be used to model inflammatory processes or host-microbe interactions in a way not previously possible with any other tissue model grown in the laboratory.

In addition, this approach is broadly applicable for the growth of miniature tissues from stem cells derived from other organs such as the lung, liver, or pancreas, and from biopsies of human patients. Our work, explained Ltolf, shows that tissue engineering can be used to control organoid development and build next-gen organoids with high physiological relevance, opening up exciting perspectives for disease modeling, drug discovery, diagnostics, and regenerative medicine.

Read this article:
Intestinal Organoid Built That Looks and Functions Like Real Tissue – Genetic Engineering & Biotechnology News

Recruiting Faculty in Molecular and Cellular Biology –

We invite applications for faculty at the levels of Assistant and Associate Professor within the Department of Molecular and Cellular Biology at Baylor College of Medicine (BCM). BCM is located within the Texas Medical Center in Houston, a premier research and clinical environment.

We are seeking motivated investigators in broad areas of normal and cancer biology, including but not limited to gene regulation, epigenetics, and synthetic biology. BCM offers competitive startup packages and our researchers are supported by outstanding core facilities providing access to dedicated expertise in Genomic, Transcriptomic, and Proteomic Profiling, Advanced and Vital Microscopy, Flow Cytometry, Stem Cell Culture, Live Bioimaging, Metabolomics, and more.

Our Department offers a collegial, collaborative environment and maintains a long-standing tradition of strong support for new faculty. Recruited faculty have the opportunity to join as members of the NCI-designated Dan L Duncan Comprehensive Cancer Center.

BCM is located in the heart of the Texas Medical Center in Houston and is affiliated with surrounding educational institutions, including the University of Texas Medical School, the UT MD Anderson Cancer Center, and Rice University.

Applications received by November 1, 2020 will receive priority.

Please send a cover letter, a CV and a 2-4 page summary of research interests to:

Baylor College of Medicine is an Equal Opportunity/Affirmative Action/Equal Access Employer

Read the original here:
Recruiting Faculty in Molecular and Cellular Biology –

Regenerative Therapy by Dr. Roshni Patel on Better CT – Farmington, CT –

This post was contributed by a community member. The views expressed here are the author’s own.

When youre in pain, its important to find effective, long-lasting solutions that can provide short recovery periods. This is what regenerative medicine offers. Over the past decade, there has been a growing field of medicine that utilizes the bodys own healing capabilities using platelet-rich plasma and mesenchymal stem cells (MSCs). This growing field is labeled as regenerative medicine. Regenerative therapies focus on healing and help regrow damaged tissue naturally. Regenerative injection therapy is used to provide relief to musculoskeletal injuries that involve damage to ligaments, tendons, cartilage, joints, and discs.

Watch video of PRP:

PRP therapy on Better CT

PRP is safeas we are using what your body naturally produces, concentrating the desired critical components and transplanting them into the affected area for effective tissue regeneration and healing. There is no risk of rejection and very minimal overall procedural risk.

FDA regulations do not allow for the cloning of stem cells or growing them in a lab. Also, stem cells derived from fat cells are not approved by the FDA as it does not allow for manipulation. This leaves us to another rich stem cell source in our body which is bone marrow. Stem cells exist in our bodies and are rudimentary cells that can differentiate into other cells.

Think of bone marrow stem cells as the mother cell that is responsible for producing new blood cells. Bone marrow contains hundreds of growth factors and is often used for severe degenerative conditions or where PRP therapy may not be sufficient to provide the growth factors needed to provide relief.

Lastly, there are many offshoot therapies that use biologics derived from placental tissue or blood cord. These biologics are sometimes marketed as Stem cells but are not stem cells and contain zero viable cells. What they contain are growth factors that can also aid when combined with PRP or Stem Cells derived from your own body.

MSCs and PRPmay be used to target a number of conditions that could benefit from their healing and regenerative qualities. Especially when considering chronic pain, alternative solutions may be necessary if it has been difficult to find relief. Along with generalized joint pain, MSCs and PRPmay be used to target:

With so many options for joint pain out there, you may be wondering what benefits choosing stem cell therapy provides. Overall, because mesenchymal stem cell therapy utilizes biologic material harvested directly from the patients body, the general benefits include minimal risk, minimal recovery time, and minimal worry:

Avoid surgery and its many complications and risks: Stem cell therapy is a minimally invasive, non-surgical procedure.

Minimal post-procedural recovery time: One of the most time-consuming factors of any injury is not always the treatment itself, but actually the recovery time. With stem cell therapy, recovery time is minimal.

No risk of rejection: Due to using biologics extracted from the patient, there is no risk of rejection.

No communicable disease transmission: As the cells originate within your own body, there is no risk of spreading disease from or to another person.

If you are suffering from joint pain, back pain, or a debilitating condition like osteoarthritis, it is important to consider all of your available options. Our elite team of professionals can determine if you are the right candidate for MSCs. If youre interested in learning more, contact us today.

Excerpt from:
Regenerative Therapy by Dr. Roshni Patel on Better CT – Farmington, CT –

California’s $7.8 Billion Proposition 14 Could Expand Conflicts of Interest in Stem Cell Research | K. Lloyd Billingsley – The Beacon

K. Lloyd Billingsley Tuesday September 15, 2020 1:15 PM PDT

Proposition 14, according to Californias legislative analyst, Authorizes Bonds to Continue Funding Stem Cell and Other Medical Research. A yes vote means the state could sell $5.5 billion in general obligation bonds primarily for stem cell research. As David Jensen notes at Capitol Weekly, theres a bit more to it.

The $5.5 billion would extend the California Institute for Regenerative Medicine (CIRM), created by the $3 billion Proposition 71 in 2004. This measure, authored by real estate developer Robert Klein, promised life-saving cures for Parkinsons Alzheimers and other diseases. A ballpark figure for the number of certified life-saving cures and therapies CIRM produced in 16 years is zero. Proposition 71 also promised more than $1 billion for state coffers, but as Jensen notes, royalties to date have totaled only $462,433. CIRM failed to accomplish its stated goal, and now it wants to conduct research on therapy delivery and aging as a pathology along with vital research opportunities, not related to stem cells.

Proposition 14 would enlarge the CIRM board from 29 to 35 members. As Jensen explains, that creates more possibilities for conflicts of interest, a long-standing issue for the agency.

In 2012, for example, the prestigious Institute of Medicine found that more than 90 percent of CIRM funding went to institutions with representatives on the CIRM governing board. Proposition 14 enlarges that board and also increases the costs to Californians.

According to the legislative analyst, we estimate the total cost to pay off the bonds would be $7.8 billion$5.5 billion for the principal and $2.3 billion for the interest. State costs would average about $260 million per year for about 30 years.

The analyst also explains a way voters can prevent this spending. A no vote means the state could not sell $5.5 billion in general obligation bonds. If voters reject Proposition 14, David Jensen explains, CIRM will begin shutting its doors this winter.

Go here to read the rest:
California’s $7.8 Billion Proposition 14 Could Expand Conflicts of Interest in Stem Cell Research | K. Lloyd Billingsley – The Beacon

GA sues therapists after making $6.4 Million on unproven products –


Carr Sues Elite Integrated Medical for Deceptive Claims Made to Elderly and Disabled Consumers Regarding Stem Cell Therapy

ATLANTA, GA Attorney General Chris Carr today filed suit against Elite Integrated Medical, LLC, formerly known as Superior Healthcare of Woodstock, LLC d/b/a Superior Healthcare Group, Superior Healthcare Sandy Springs, and Superior Healthcare Morrow, along with its owner, Justin Paulk, (collectively Elite) for allegedly violating the Georgia Fair Business Practices Act (FBPA) by making false and misleading claims about the regenerative medicine products they offered to Georgia consumers.

The use of unproven products or therapies can be harmful to consumers health and/or set them back thousands of dollars without affording them any results, said Attorney General Chris Carr. Our office will continue to hold accountable businesses that make unsubstantiated claims and violate the law.

The complaintcontends that Elite made over $6.4 million by using aggressive marketing techniques and high-pressure sales tactics to convince at least 842 consumers, most of whom were elderly and/or disabled, to purchase expensive, unproven medical treatments that are not covered by Medicare or health insurance. The office seeks injunctive relief, consumer restitution and civil penalties of up to $5,000 per violation of the FBPA and up to $10,000 per FBPA violation committed against elderly and/or disabled consumers.

According to the complaint, Elite represents that it has a staff of medical doctors who provide its products to patients, when in fact, medical doctors administer a very limited number of product injections. The vast majority of patients interact only with chiropractors and nurse practitioners, and most of the injections are administered by nurse practitioners.

The Attorney Generals office also alleges that Elite acted deceptively by featuring on its website a customer testimonial from a purported customer who is actually an owner of Elites advertising agency, without disclosing the material connections between itself and this person or the fact that this customer received his treatments for free.

It should be noted that the Attorney Generals Office has also reached a settlement with Grow Smart Marketing, LLC and its two owners, who were responsible for writing content for Elite Integrated Medicals website, social media ads, and emails about upcoming seminars. The settlement requires the company to refrain from making unsubstantiated claims on behalf of its clients who market stem cell therapy products to Georgia consumers and to pay restitution to the state.

Warnings and Tips for Consumers

The U.S. Food and Drug Administration (FDA) has warned consumers of the potential dangers associated with unapproved stem cell, exosome and other products marketed as regenerative medicine products, which include administration site reactions; the ability of cells to move from placement sites and change into inappropriate cell types or multiply; failure of cells to work as expected; and the growth of tumors. Using unapproved regenerative medicine products that have no proven clinical benefit could also end up delaying a proper diagnosis or discouraging patients with serious illnesses from getting safe and effective treatments.

The FDA encourages consumers who are considering regenerative medicine therapies to consider the following advice and information:

See original here:
GA sues therapists after making $6.4 Million on unproven products –

NK Cell Therapy and Stem Cell Therapy Market Report 2020 (COVID-19 Impact Analysis) By Segmentations, Key Company Profiles & Demand Forecasts to…

NK Cell Therapy and Stem Cell Therapy Market has been riding a progressive growth trail over the recent past. The first two quarters of the year 2020 have however witnessed heavy disruptions throughout all the industry facets, which are ultimately posing an unprecedented impact on NK Cell Therapy and Stem Cell Therapy market. Although healthcare & life sciences industry as a whole is witnessing an influx of opportunities in selected sectors, it remains a matter of fact that some of the industry sectors have temporarily scaled back. It becomes imperative to stay abreast of all the recent updates and predict the near future wisely.

The report primarily attempts to track the evolution of growth path of market from 2019, through 2020, and post the crisis. It also provides long-term market growth projections for a predefined period of assessment, 2015 2026. Based on detailed analysis of industrys key dynamics and segmental performance, the report offers an extensive assessment of demand, supply, and manufacturing scenario. Upsurge in R&D investments, increasing sophistication of healthcare infrastructure, thriving medical tourism, and rapidly introducing innovations in NK Cell Therapy and Stem Cell Therapy and equipment sector are thoroughly evaluated.

For Better Understanding, Download FREE Sample Copy of NK Cell Therapy and Stem Cell Therapy Report @

Key players in the global NK Cell Therapy and Stem Cell Therapy market covered in Chapter 4:

Chipscreen Biosciences Innate Pharma SA Osiris Therapeutics Chiesi Pharmaceuticals Molmed JCR Pharmaceutical Altor BioScience Corporation Affimed NV Takeda Pharmaceutical Pharmicell Medi-post NuVasive Anterogen

In Chapter 11 and 13.3, on the basis of types, the NK Cell Therapy and Stem Cell Therapy market from 2015 to 2026 is primarily split into:

NK Cell Therapy Stem Cell Therapy

In Chapter 12 and 13.4, on the basis of applications, the NK Cell Therapy and Stem Cell Therapy market from 2015 to 2026 covers:

Hospital & clinics Regenerative medicine centers Diagnostic centers Research institutes Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

Direct Purchase NK Cell Therapy and Stem Cell Therapy Market Research Report @

Some Points from Table of Content

Global NK Cell Therapy and Stem Cell Therapy Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Chapter 1Report Overview

Chapter 2 Global Market Growth Trends

Chapter 3 Value Chain of NK Cell Therapy and Stem Cell Therapy Market

Chapter 4 Players Profiles

Chapter 5 Global NK Cell Therapy and Stem Cell Therapy Market Analysis by Regions

Chapter 6 North America NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 7 Europe NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 8 Asia-Pacific NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 9 Middle East and Africa NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 10 South America NK Cell Therapy and Stem Cell Therapy Market Analysis by Countries

Chapter 11 Global NK Cell Therapy and Stem Cell Therapy Market Segment by Types

Chapter 12 Global NK Cell Therapy and Stem Cell Therapy Market Segment by Applications

Chapter 13 NK Cell Therapy and Stem Cell Therapy Market Forecast by Regions (2020-2026)

Chapter 14 Appendix

Impact of Covid-19 in NK Cell Therapy and Stem Cell Therapy Market: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the NK Cell Therapy and Stem Cell Therapy market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Points Covered in the Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Contact for Any Query or Get Customized Report @

Contact Us

Credible Markets Analytics

99 Wall Street 2124 New York, NY 10005

US Contact No: +1(929)-450-2887

Email: [emailprotected]

Thanks for reading this article you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

View original post here:
NK Cell Therapy and Stem Cell Therapy Market Report 2020 (COVID-19 Impact Analysis) By Segmentations, Key Company Profiles & Demand Forecasts to…

LifeGaines Medical and Aesthetics Center in Boca Raton Helps Patients Stay Young and Healthy – Yahoo Finance


So far, September has been a wild ride of ups and downs. Following the recent bout of volatility, stocks have ticked higher again. But as uncertainty regarding another rescue program and the presidential election continues to linger, where does the market go from here? Weighing in for Oppenheimer, Chief Investment Strategist John Stoltzfus argues that any market dips appear relatively contained and orderly, and present longer-term investors the chance to find babies that got thrown out with the bathwater. He noted, For nervous investors the recent downdraft has presented opportunity to take some profits without FOMO (fear of missing out).As for the tech heavyweights that powered the markets five-month charge forward, the strategist believes current expectations that technology stocks will remain under pressure for some time seem exaggerated. Stoltzfus adds that the core of technology stocks did not appear terribly rich in price considering that developments in technology and innovation have yet to show signs of plateauing in the current cycle.Taking Stoltzfus outlook into consideration, our focus turned to stocks that Oppenheimer analysts are bullish on. The firm’s pros see triple-digit upside potential in store for three tickers in particular. Running the names through TipRanks database, we wanted to find out what makes each so compelling.MediWound Ltd. (MDWD)Developing cutting-edge products, MediWound wants to address unmet needs in the fields of severe burn and chronic wound management. With an important government contract secured, Oppenheimer has high hopes for this name.Back in January, MDWD announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) had entered into a contract to procure $16.5 million of NexoBrid, its drug designed to remove eschar in adults with deep partial and full-thickness thermal burns (a process called debridement), for an emergency stockpile. According to management, the first delivery is set for Q3 2020.On top of this, the company filed the NexoBrid Biologics License Application (BLA) with the FDA for eschar removal in adults with deep partial-thickness and full-thickness thermal burns in June. MDWDs U.S. commercial partner, Vericel, is preparing for an immediate launch upon approval.Representing Oppenheimer, 5-star analyst Kevin DeGeeter points out that Given the filing involved participation from three partiesMDWD, U.S. commercial partner Vericel and funding partners at BARDAand was completed against the backdrop of public sector work-from-home mandates, we view meeting stated timelines as a material milestone and derisking event for MDWD shares… we believe NexoBrid is on track for 1H21 launch.Should the therapy ultimately be approved, MDWD is entitled to a $7.5 million milestone payment from Vericel. We believe the combination of existing cash and the $7.5 million milestone payment from VCEL upon NexoBrid approval should fund operations at least into 2H23, DeGeeter added.DeGeeter also points out that MDWD plans to open 25-30 sites in U.S. and Israel to support the Phase 2 study of EscharEx, its product for chronic wounds. Although COVID-19 resulted in a delay, the analyst thinks the current timeline of 1H21 is achievable.To this end, DeGeeter rates MDWD an Outperform along with a $7 price target. Should his thesis play out, a potential twelve-month gain of 117% could be in the cards. (To watch DeGeeters track record, click here)All in all, other analysts echo DeGeeters sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $6.63, the upside potential comes in at 106%. (See MDWD stock analysis on TipRanks)UroGen Pharma (URGN)Primarily focused on uro-oncology, UroGen Pharma develops advanced non-surgical treatments to improve the lives of patients. As the launch of one of its products is progressing well, Oppenheimer thinks that now is the time to get on board.Writing for the firm, analyst Leland Gershell points to UGN-101 as a key component of his bullish thesis. UGN-101, which has now been formally launched in the U.S. under the commercial name Jelmyto, was designed as a treatment for low-grade upper tract urothelial carcinoma (LG UTUC). The analyst highlights that Jelmytos launch is already off to a solid start, as eight patients had received 20 doses of the drug in June.Jelmyto sales were $371,000 in its first month of launch, but more important was management’s commentary that over 100 urology practice sites are treatment-ready for the product, and that patient demand has not been visibly impacted by COVID-19, Gershell explained.Adding to the good news, permanent C- and J-codes, which are expected in October and January 2021, respectively, could bolster sales, in Gershells opinion. The label could also be updated to reflect completed OLYMPUS data.It should be noted that patient and physician engagement could remain diminished through YE20, and restrictions around elective surgeries could persist, according to Gershell. That said, he argues that LG UTUC’s lack of surgical urgency could imply treatment deferral for several months, whereas Jelmyto’s ability to be administered in an outpatient setting could expedite treatment, favoring adoption.If that wasnt enough, UGN-102, its mitomycin gel that targets low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC), is set to enter pivotal testing before the end of 2020. Looking at previously released data, the therapy achieved a 65% complete response (CR) rate at three months following onset of treatment. To offset any potential COVID-19 impact on enrollment, URGN has increased the number of clinical trial sites outside of the U.S., in those countries where virus-related clinical delays have not cropped up,Gershell added.Summing it all up, Gershell commented, We believe shares trade at a discount to the value of Jelmyto and UGN-102, and that revenue growth will support stock upside over the next 12 months.To this end, Gershell stands with the bulls, reiterating an Outperform rating. At $48, his price target brings the upside potential to 123%. (To watch Gershells track record, click here)What does the rest of the Street have to say? 3 Buy ratings and 1 Hold have been issued in the last three months. As a result, URGN receives a Strong Buy consensus rating. In addition, the $44 average price target suggests 104% upside potential. (See URGN stock analysis on TipRanks)Ayala Pharmaceuticals Inc. (AYLA)Last but not least we have Ayala Pharmaceuticals, which is focused on developing targeted therapies for cancers in which Notch activation is a known tumor driver. Based on the progress across its development pipeline, Oppenheimer sees big gains in store.Oppenheimer analyst Jay Olson thinks AYLAs technology makes it a stand-out. Its two candidates, AL101 and AL102, which are in-licensed from Bristol Myers, are gamma-secretase inhibitors that target aberrant activation of Notch signaling in cancer cells.Notch signaling plays an important role in normal cell development, and perturbations can cause malignant transformation. We believe Notch targeted therapies hold promise in addressing unmet clinical needs, Olson commented.The analyst added, The Notch mutational landscape is diverse, and the underlying science is evolving. AYLA is building a bioinformatics database around Notch to better characterize and identify Notch-activating mutations. Additionally, AYLA is collaborating with partners developing diagnostic tests for Notch-activating mutations, both at DNA and RNA levels. We believe these initiatives benefit AYLA in the long term by identifying responders and expanding the addressable patient population.Despite the challenges presented by COVID-19, critical catalysts remain on track. The company is set to present new interim data from the Phase 2 ACCURACY open-label study of AL101 in R/M ACC at the mini oral head and neck cancer section of ESMO. Looking at the available data, a recent interim analysis in one cohort showed 69% DCR.As for the second cohort, it is evaluating a 6mg once-weekly dosing of AL101. We view the efficacy and safety data from the 6mg dosing cohort as important for the registration-enabling studies, and we anticipate similar interim data readout in 1H21, Olson said.Adding to the good news, AYLA is on track to kick off patient dosing in the Phase 2 TENACITY study of AL101 in R/M TNBC by YE20 after the IND was cleared by the FDA in April. In 2021, AYLA plans to initiate two additional Phase 2 studies including AL102 for desmoid tumors and AL101 for r/r T-ALL.Springworks Therapeutics recently announced the completion of patient enrollment of the Phase 3 DeFi trial of nirogacestat in desmoid tumors with topline data expected mid-2021, which should provide read-across to AYLA’s AL102 program, Olson noted.Given all of the above, Olson opined, We’re encouraged by AYLA’s advantages along several dimensions, including its drug candidates, cancer indication selection, and focus on identifying Notch-activating mutations while developing diagnostics. AYLA’s Notch targeted approach should address unmet clinical needs for patients with rare but aggressive cancers.It should come as no surprise, then, that Olson stayed with the bulls. To this end, he kept an Outperform rating and $23 price target on the stock, implying 123% upside potential. (To watch Olsons track record, click here)Looking at the consensus breakdown, 2 Buys and 1 Hold have been published in the last three months. Therefore, AYLA gets a Moderate Buy consensus rating. Based on the $19.83 average price target, shares could climb 92% higher in the next year. (See AYLA stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Go here to see the original:
LifeGaines Medical and Aesthetics Center in Boca Raton Helps Patients Stay Young and Healthy – Yahoo Finance

New research connects the hormones we’re born with to lifetime risk for immunological diseases – MSUToday

Differences in biological sex can dictate lifelong disease patterns, says a new study by Michigan State University researchers that links connections between specific hormones present before and after birth with immune response and lifelong immunological disease development.

Published in the most recent edition of the Proceedings of the National Academy of Sciences, the study answers questions about why females are at increased risk for common diseases that involve or target the immune system like asthma, allergies, migraines and irritable bowel syndrome. The findings by Adam Moeser, Emily Mackey and Cynthia Jordan also open the door for new therapies and preventatives

This research shows that its our perinatal hormones, not our adult sex hormones, that have a greater influence on our risk of developing mast cell-associated disorders throughout the lifespan, says Moeser, Matilda R. Wilson Endowed Chair, professor in the Department of Large Animal Clinical Sciences and the studys principle investigator. A better understanding of how perinatal sex hormones shape lifelong mast cell activity could lead to sex-specific preventatives and therapies for mast cell-associated diseases.

Mast cells are white blood cells that play beneficial roles in the body. They orchestrate the first line of defense against infections and toxin exposure and play an important role in wound healing, according to the study, Perinatal Androgens Organize Sex Differences in Mast Cells and Attenuate Anaphylaxis Severity into Adulthood.

However, when mast cells become overreactive, they can initiate chronic inflammatory diseases and, in certain cases, death. Moesers prior research linked psychological stress to a specific mast cell receptor and overreactive immune responses.

Moeser also previously discovered sex differences in mast cells. Female mast cells store and release more inflammatory substances like proteases, histamine and serotonin, compared with males. Thus, female mast cells are more likely than male mast cells to kick-start aggressive immune responses. While this may offer females the upper hand in surviving infections, it also can put females at higher risk for inflammatory and autoimmune diseases.

IBS is an example of this, says Mackey, whose doctoral research is part of this new publication.

While approximately 25% of the U.S. population is affected by IBS, women are up to four times more likely to develop this disease than men.

Moeser, Mackey and Jordans latest research explains why these sex-biased disease patterns are observed in both adults and prepubertal children. They found that lower levels of serum histamine and less-severe anaphylactic responses occur in males because of their naturally higher levels of perinatal androgens, which are specific sex hormones present shortly before and after birth.

Mast cells are created from stem cells in our bone marrow, Moeser said. High levels of perinatal androgens program the mast cell stem cells to house and release lower levels of inflammatory substances, resulting in a significantly reduced severity of anaphylactic responses in male newborns and adults.

We then confirmed that the androgens played a role by studying males who lack functional androgen receptors, says Jordan, professor of Neuroscience and an expert in the biology of sex differences.

While high perinatal androgen levels are specific to males, the researchers found that while in utero, females exposed to male levels of perinatal androgens develop mast cells that behave more like those of males.

For these females, exposure to the perinatal androgens reduced their histamine levels and they also exhibited less-severe anaphylactic responses as adults, says Mackey, who is currently a veterinary medical student at North Carolina State University.

In addition to paving the way for improved and potentially novel therapies for sex-biased immunological and other diseases, future research based will help researchers understand how physiological and environmental factors that occur early in life can shape lifetime disease risk, particularly mast cell-mediated disease patterns.

While biological sex and adult sex hormones are known to have a major influence on immunological diseases between the sexes, were learning that the hormones that we are exposed to in utero may play a larger role in determining sex differences in mast cell-associated disease risk, both as adults and as children, Moeser said.

For more information on Moesers research, go to the Gastrointestinal Stress Biology Laboratory. Also, visit the MSU College of Veterinary Medicines website for more about its research efforts.

(Note for media: Please include the following link to the study in all online media coverage:

New research connects the hormones we’re born with to lifetime risk for immunological diseases – MSUToday